Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of fluorouracil in humans.

Literature DB >> 688233

Pharmacokinetics of fluorouracil in humans.

W E MacMillan, W H Wolberg, P G Welling.

Abstract

A high-pressure liquid chromatography method has been used to investigate the pharmacokinetics of fluorouracil after single i.v. doses to patients. The method is simple and is specific for fluorouracil. No interference was observed in fluorouracil determinations due to other administered medication. Plasma levels of fluorouracil declined rapidly after dosing. The mean half-life was 11.4 min, and drug was essentially cleared from plasma in 1 hr. Individual differences in plasma fluorouracil levels, and also in derived pharmacokinetic constants, were considerably less than those reported previously.

Entities: Chemical Species

Mesh：

Substances：
Fluorouracil

Year: 1978 PMID： 688233

Source DB: PubMed Journal: Cancer Res ISSN： 0008-5472 Impact factor: 12.701

Keyword Cloud
Cited

17 in total

1. Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-fluorouracil.

Authors: J F Belliveau; M R Posner; G W Crabtree; A B Weitberg; M C Wiemann; F J Cummings; G P O'Leary; E Ingersoll; P Calabresi
Journal: Eur J Clin Pharmacol Date: 1991 Impact factor: 2.953

2. Ultrasound-activated agents comprised of 5FU-bearing nanoparticles bonded to microbubbles inhibit solid tumor growth and improve survival.

Authors: Caitlin W Burke; Eben Alexander; Kelsie Timbie; Alexander L Kilbanov; Richard J Price
Journal: Mol Ther Date: 2013-10-31 Impact factor: 11.454

3. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique.

Authors: H J Wanebo; M A Chung; A I Levy; P S Turk; M P Vezeridis; J F Belliveau
Journal: Ann Surg Oncol Date: 1996-05 Impact factor: 5.344

Review 4. The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors: C Erlichman; R C Donehower; B A Chabner
Journal: Cancer Chemother Pharmacol Date: 1980 Impact factor: 3.333

5. The clinical syndrome of 5-fluorouracil cardiotoxicity.

Authors: J F Ensley; B Patel; R Kloner; J A Kish; J Wynne; M al-Sarraf
Journal: Invest New Drugs Date: 1989-04 Impact factor: 3.850

6. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.

Authors: Steven M Offer; Natalie J Wegner; Croix Fossum; Kangsheng Wang; Robert B Diasio
Journal: Cancer Res Date: 2013-01-17 Impact factor: 12.701

Pharmacokinetics of fluorouracil in humans.

1. Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-fluorouracil.

2. Ultrasound-activated agents comprised of 5FU-bearing nanoparticles bonded to microbubbles inhibit solid tumor growth and improve survival.

3. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique.

Review 4. The practical benefits of pharmacokinetics in the use of antineoplastic agents.

5. The clinical syndrome of 5-fluorouracil cardiotoxicity.

6. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.

7. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids.

8. Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva.

9. Antitumor effect of intratumoral administration of fluorouracil/epinephrine injectable gel in C3H mice.

Review 10. Clinical pharmacokinetics of commonly used anticancer drugs.